Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient.
作者信息
Hill Joshua A, Ujjani Chaitra S, Greninger Alexander L, Shadman Mazyar, Gopal Ajay K
机构信息
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
出版信息
Cancer Cell. 2021 Aug 9;39(8):1037-1038. doi: 10.1016/j.ccell.2021.06.015. Epub 2021 Jun 26.
Abstract
摘要
相似文献
1
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient.一名淋巴瘤患者接种新冠疫苗失败后接种异源新冠疫苗的免疫原性
Cancer Cell. 2021 Aug 9;39(8):1037-1038. doi: 10.1016/j.ccell.2021.06.015. Epub 2021 Jun 26.
2
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.慢性透析患者 COVID-19 疫苗接种的免疫原性。
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.
3
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
[The value of booster vaccination against COVID-19].[新冠病毒加强针接种的价值]
Ned Tijdschr Geneeskd. 2021 Dec 23;165:D6623.
6
Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.接种 Covishield 和辉瑞 SARS-CoV-2 疫苗可引发强烈的体液免疫反应。
J Infect Dev Ctries. 2021 May 31;15(5):653-656. doi: 10.3855/jidc.15368.
7
Behavioral and social science in support of SARS-CoV-2 vaccination: National Institutes of Health initiatives.支持 SARS-CoV-2 疫苗接种的行为和社会科学：美国国立卫生研究院的举措。
Transl Behav Med. 2021 Jul 29;11(7):1354-1358. doi: 10.1093/tbm/ibab067.
8
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.新型冠状病毒候选载体疫苗 MVA-SARS-2-S 的免疫原性和疗效的临床前疫苗接种研究。
Proc Natl Acad Sci U S A. 2021 Jul 13;118(28). doi: 10.1073/pnas.2026207118.
9
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.风湿科医师新加坡分会关于风湿性疾病患者接种 COVID-19 疫苗的建议。
Int J Rheum Dis. 2021 Jun;24(6):746-757. doi: 10.1111/1756-185X.14107. Epub 2021 May 10.
10
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.一种基于人体细胞的 SARS-CoV-2 疫苗可引发强烈的中和抗体反应，并可保护小鼠免受 SARS-CoV-2 攻击。
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
引用本文的文献
1
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
2
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.芦可替尼治疗骨髓纤维化和真性红细胞增多症后，使用BNT162b2 mRNA新冠疫苗进行标准和加强接种会导致体液免疫反应欠佳。
Front Oncol. 2023 Feb 14;13:1117815. doi: 10.3389/fonc.2023.1117815. eCollection 2023.
3
Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.血液系统恶性肿瘤患者对新冠疫苗接种的免疫反应：一篇综述
Chonnam Med J. 2023 Jan;59(1):24-30. doi: 10.4068/cmj.2023.59.1.24. Epub 2023 Jan 25.
4
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.先前接受过异源新冠病毒灭活疫苗/牛津-阿斯利康腺病毒载体疫苗基础免疫的实体癌患者接种第三剂新冠mRNA加强疫苗后的免疫原性。
Vaccines (Basel). 2022 Sep 26;10(10):1613. doi: 10.3390/vaccines10101613.
5
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.一项系统评价和荟萃分析：成人血液恶性肿瘤患者对 SARS-CoV-2 疫苗首剂和第 2 剂的免疫应答。
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.
6
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.癌症患者接种疫苗后对 SARS-CoV-2 关注变体的适应性免疫和中和抗体：CAPTURE 研究。
Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.
7
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.通过疫情学习：关于 COVID-19 和癌症的现有知识状况。
Cancer Discov. 2022 Feb;12(2):303-330. doi: 10.1158/2159-8290.CD-21-1368. Epub 2021 Dec 10.
8
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.COVID-19 疫苗在血液系统恶性肿瘤患者中的免疫原性：系统评价和荟萃分析。
Blood Adv. 2022 Apr 12;6(7):2014-2034. doi: 10.1182/bloodadvances.2021006333.
9
Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.B细胞淋巴恶性肿瘤患者的异源严重急性呼吸综合征冠状病毒2疫苗接种
Am J Hematol. 2022 Feb 1;97(2):E67-E69. doi: 10.1002/ajh.26418. Epub 2021 Nov 30.
10
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.癌症患者对新冠疫苗接种的抗体反应：一项系统评价
Front Oncol. 2021 Nov 4;11:759108. doi: 10.3389/fonc.2021.759108. eCollection 2021.
本文引用的文献
1
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性：一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
2
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.mRNA 疫苗在癌症患者中的免疫原性。
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
3
Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.AdviseDx SARS-CoV-2 抗体检测试剂盒检测的抗 SARS-CoV-2 抗体水平与先前可用的血清学检测方法一致，但不能完全预测是否具有中和抗体。
J Clin Microbiol. 2021 Aug 18;59(9):e0098921. doi: 10.1128/JCM.00989-21.
4
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
5
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第三剂新冠病毒疫苗的安全性和免疫原性：病例系列
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
6
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
7
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.布罗顿酪氨酸激酶抑制剂对佐剂重组乙型肝炎和带状疱疹疫苗疗效的影响。
Blood. 2021 Jan 14;137(2):185-189. doi: 10.1182/blood.2020008758.
8
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
9
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.用于中和测定的用 SARS-CoV-2 刺突蛋白假型化慢病毒颗粒的方案和试剂。
Viruses. 2020 May 6;12(5):513. doi: 10.3390/v12050513.
10
Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine.既往对乙肝疫苗无应答者对双倍剂量甲乙肝联合疫苗的应答率良好。
J Infect Dis. 2008 Aug 1;198(3):299-304. doi: 10.1086/589722.
Zotero 插件